EyePoint Pharmaceuticals, Inc. (EYPT)

Market Cap	684.68M
Revenue (ttm)	56.04M
Net Income (ttm)	-146.78M
Shares Out	68.81M
EPS (ttm)	-2.43
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,047,056
Open	9.82
Previous Close	9.49
Day's Range	9.76 - 10.01
52-Week Range	3.91 - 13.99
Beta	1.69
Analysts	Strong Buy
Price Target	24.75 (+149.25%)
Earnings Date	Aug 6, 2025

About EYPT

EyePoint Pharmaceuticals, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related ma...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 27, 2005
• Employees: 165
• Stock Exchange: NASDAQ
• Ticker Symbol: EYPT
• Website: https://eyepointpharma.com

Financial Performance

In 2024, EyePoint Pharmaceuticals's revenue was $43.27 million, a decrease of -5.97% compared to the previous year's $46.02 million. Losses were -$130.87 million, 84.9% more than in 2023.

Analyst Summary

According to 8 analysts, the average rating for EYPT stock is "Strong Buy." The 12-month stock price target is $24.75, which is an increase of 149.25% from the latest price.

Price Target

$24.75

(149.25% upside)

Analyst Consensus: Strong Buy